睿知中国医院研究地图
候选清单

即将招募乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07139470,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or pathological specimen, including:

    入选标准第 2 条

    Definition of human epidermal growth factor receptor 2 (HER2) negative: immunohistochemistry (IHC) of 0 or 1+; if HER is 2+ by IHC, negative HER2 expression must be confirmed by fluorescence in situ hybridization (FISH);

    入选标准第 3 条

  3. For neoadjuvant and/or adjuvant chemotherapy, if relapse or disease progression to unresectable locally advanced or metastatic disease occurs during treatment or within 12 months after discontinuation of treatment (at least 2 cycles have been completed), it will be considered as one of the standard of care regimens;

    入选标准第 7 条

    For patients with documented germline BRCA1/BRCA2 mutations, if they have been treated with an approved PARP inhibitor, then the PARP inhibitor can be considered as one prior standard of care regimens required;

    入选标准第 8 条

    Newly diagnosed brain metastases at screening must be stable for ≥4 weeks after local treatment (e.g., radiotherapy) with imaging confirmation.

    入选标准第 10 条

    Major surgery within 4 weeks prior to dosing or expected to require major surgery during the study period.

    排除标准第 29 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

    入选标准第 12 条

  5. Hematology: neutrophil count (NEUT) ≥ 1.5 × 10\^9/L; platelets (PLT) ≥ 100 × 10\^9/L; hemoglobin ≥ 90g/L;

    入选标准第 15 条

    Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN), for patients with liver metastases, ALT and AST must be ≤ 5 × ULN; Albumin ≥ 30g/L; total bilirubin (TBIL) ≤ 1.5 × ULN;

    入选标准第 16 条

    Renal function: creatinine clearance (Ccr) ≥ 50 ml/min;

    入选标准第 17 条

    Coagulation function: international normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5 × ULN.

    入选标准第 18 条

  6. Patients must have at least one measurable lesion per RECIST v1.1 criteria; those with only skin or bone lesions cannot be included.

    入选标准第 11 条

  7. Within 3 years before administration having other malignancies (except for those cured by local treatment, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, etc.).

    排除标准第 7 条

    Having an active autoimmune disease requiring systemic treatment in the past two years (including but not limited to: autoimmune hepatitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, etc.), systemic treatment includes disease-modifying drugs, immunosuppressants, systemic corticosteroids (> 10 mg/day prednisone or equivalent). Hormone replacement therapy, such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a systemic treatment; within2weeks before administration> 10 mg/day prednisone systemic corticosteroid treatment or other immunosuppressive drugs.

    排除标准第 22 条

    Human Immunodeficiency Virus (HIV) test positive or history of Acquired Immunodeficiency Syndrome (AIDS); known active syphilis infection.

    排除标准第 27 条

  8. Patients of childbearing potential (male or female) must use effective medical contraception from consent until 6 months after the end of the dosing period.

    入选标准第 19 条

    Pregnant or breastfeeding women.

    排除标准第 35 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07139470,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years at the time of signing informed consent.
  2. Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or pathological specimen, including:
  3. Definition of human epidermal growth factor receptor 2 (HER2) negative: immunohistochemistry (IHC) of 0 or 1+; if HER is 2+ by IHC, negative HER2 expression must be confirmed by fluorescence in situ hybridization (FISH);
  4. Estrogen and progesterone receptor negative means that less than 1% of the cells express hormone receptors as indicated by IHC.
  5. Patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least one line of standard of care regimens, including:
  6. Any treatment received by the patients regardless of triple-negative state can be included as one of the standard of care regimens;
  7. For neoadjuvant and/or adjuvant chemotherapy, if relapse or disease progression to unresectable locally advanced or metastatic disease occurs during treatment or within 12 months after discontinuation of treatment (at least 2 cycles have been completed), it will be considered as one of the standard of care regimens;
  8. For patients with documented germline BRCA1/BRCA2 mutations, if they have been treated with an approved PARP inhibitor, then the PARP inhibitor can be considered as one prior standard of care regimens required;
  9. Patients must have progressed on or were intolerable to the treatment during or after the last treatment prior to enrollment.
  10. Newly diagnosed brain metastases at screening must be stable for ≥4 weeks after local treatment (e.g., radiotherapy) with imaging confirmation.
  11. Patients must have at least one measurable lesion per RECIST v1.1 criteria; those with only skin or bone lesions cannot be included.
  12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  13. With an expected survival of ≥ 12 weeks.
  14. Patients must have adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin, or colony stimulating factor therapy has been received within 2 weeks prior to the treatment), which is defined as follows:
  15. Hematology: neutrophil count (NEUT) ≥ 1.5 × 10\^9/L; platelets (PLT) ≥ 100 × 10\^9/L; hemoglobin ≥ 90g/L;
  16. Liver function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN), for patients with liver metastases, ALT and AST must be ≤ 5 × ULN; Albumin ≥ 30g/L; total bilirubin (TBIL) ≤ 1.5 × ULN;
  17. Renal function: creatinine clearance (Ccr) ≥ 50 ml/min;
  18. Coagulation function: international normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5 × ULN.
  19. Patients of childbearing potential (male or female) must use effective medical contraception from consent until 6 months after the end of the dosing period.
  20. Patients voluntarily participate in the study, sign the informed consent form, and will be able to comply with the protocol-specified visits and relevant procedures.

排除标准:Exclusion Criteria:

  1. Previously received any of the following treatments (including in the adjuvant or neoadjuvant setting):
  2. TargetedTROP2therapy;
  3. Any drug treatment targeting topoisomeraseI, including antibody-drug conjugates (ADC) therapy;
  4. Anti-angiogenic drugtherapy.
  5. Patients with multiple factors affecting oral medication.
  6. Known to have meningeal metastasis, brainstem metastasis, spinal cord metastasis, and/or compression, active central nervous system (CNS) metastasis. Patients with previously treated brain metastases can participate if clinically stable for at least 4 weeks before dosing and do not require corticosteroids or anticonvulsants for at least 14 days. Patients with untreated asymptomatic brain metastases must require investigator approval.
  7. Within 3 years before administration having other malignancies (except for those cured by local treatment, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, etc.).
  8. Presence of any of the following cardiovascular diseases or risk factors:
  9. Within 6 months before administration, myocardial infarction, unstable angina, acute or persistent myocardial ischemia, grade 3 or grade 4 heart failure, symptomatic or poorly controlled severe arrhythmias, cerebrovascular accident, transient ischemic attack, and other severe cardiovascular diseases;
  10. History of myocarditis, primary cardiomyopathy, specific cardiomyopathy, and other myocardial diseases;
  11. Within 3 months before administration, any deep vein thrombosis (if stabilized by low molecular weight heparin or similar drugs≥ 2 weeks, enrollment is allowed), peripheral arterial thromboembolism, pulmonary embolism, or other severe thromboembolic events;
  12. Presence of aortic aneurysm, aortic dissection aneurysm, or other major vascular diseases that may be life-threatening or require surgery within 6 months before administration.
  13. Uncontrollable systemic diseases as judged by the investigator:
  14. Poorly controlled diabetes (fasting blood glucose≥ 10 mmol/L on two consecutive occasions);
  15. Poorly controlled hypertension (systolic blood pressure> 160 mmHg and/or diastolic blood pressure> 100 mmHg);
  16. Presence of clinically symptomatic or requiring repeated drainage of pleural effusion, pericardial effusion, or ascites (> 1 time/week).
  17. Presence of steroid-requiring (non-infectious) interstitial lung disease (ILD) or a history of non-infectious pneumonia, currently having ILD or non-infectious pneumonia, or suspected ILD or non-infectious pneumonia that cannot be ruled out by imaging at screening.
  18. Clinically significant lung damage due to pulmonary complications, including but not limited to any underlying lung disease or any autoimmune, connective tissue, or inflammatory disease that may involve the lungs, or previous total pneumonectomy.
  19. Patients with active chronic inflammatory bowel disease, gastrointestinal obstruction, severe ulcers, gastrointestinal perforation, abdominal abscess, or acute gastrointestinal bleeding.
  20. Patients with acute gastrointestinal bleeding, persistent bleeding disorders, or bleeding tendencies such as coagulopathy.
  21. Toxicity from previous anti-tumor treatments has not recovered to ≤ 1grade (based on NCI CTCAE v5.0 assessment) or to the level specified by the inclusion criteria (excluding toxicities such as alopecia, fatigue, etc., judged by the investigator to be of low safety risk).
  22. Having an active autoimmune disease requiring systemic treatment in the past two years (including but not limited to: autoimmune hepatitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, etc.), systemic treatment includes disease-modifying drugs, immunosuppressants, systemic corticosteroids (> 10 mg/day prednisone or equivalent). Hormone replacement therapy, such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a systemic treatment; within2weeks before administration> 10 mg/day prednisone systemic corticosteroid treatment or other immunosuppressive drugs.
  23. Known active tuberculosis.
  24. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  25. With ≥ 2 grade peripheral neuropathy.
  26. Active hepatitis B or hepatitis C.
  27. Human Immunodeficiency Virus (HIV) test positive or history of Acquired Immunodeficiency Syndrome (AIDS); known active syphilis infection.
  28. Known allergy to the study drug or any of its components, known history of severe hypersensitivity to other biological products.
  29. Major surgery within 4 weeks prior to dosing or expected to require major surgery during the study period.
  30. Severe infection within 4 weeks prior to dosing, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective treatment within 2 weeks prior to dosing.
  31. Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or history of corneal disease that impedes delayed corneal healing.
  32. Non-specific immunomodulatory treatment within 2 weeks prior to dosing (including but not limited to interferon,IL-2), approved traditional Chinese medicine preparations for anti-tumor indications, etc.
  33. Prior to dosing 30 days after receiving a live vaccine, or planning to receive a live vaccine during the study period.
  34. Rapid deterioration of the condition during the screening before administration, such as significant changes in physical status.
  35. Pregnant or breastfeeding women.
  36. Suffering from local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which may lead to high medical risk and/or uncertainty in survival evaluation, such as tumor leukemic reactions, cachexia manifestations, etc.
  37. Any condition that the researcher believes interferes with the evaluation of the study drug or the safety of the subject or the interpretation of the study results, or any other condition that the investigator believes is not suitable for participation in this study.

引自 ClinicalTrials.gov, NCT07139470, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07139470,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07139470